Meriofert

Follicle-Stimulating Hormone, Luteinising Hormone, the active ingredients in Meriofert, are gonadotropins presented as a sterile injectable solution for subcutaneous use. They are employed to stimulate ovarian follicular development and ovulation in women with specific reproductive disorders.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use. Customers receive dedicated technical support and assurance of product integrity throughout the supply chain.

Meriofert, a gonadotropin preparation, is used in reproductive medicine to address disorders of ovarian function. - Infertility due to anovulation: promotes follicular growth and ovulation in women who do not ovulate spontaneously. - Controlled ovarian stimulation for assisted reproductive technologies: enhances multiple follicle development to increase oocyte yield for IVF or ICSI cycles. - Hypogonadotropic hypogonadism: replaces deficient endogenous FSH and LH to restore normal ovarian activity.

Meriofert may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Injection site pain: mild discomfort or tenderness at the subcutaneous injection site. - Headache: transient headache occurring shortly after administration. - Nausea: mild nausea that usually resolves without intervention. - Ovarian hyperstimulation symptoms: abdominal bloating, mild pelvic discomfort.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS): severe ovarian enlargement, fluid shift, and risk of thromboembolism. - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Allergic reactions: rash, urticaria, or anaphylaxis.

Prior to initiating Meriofert therapy, clinicians should consider several safety precautions to minimize risks. - Assess baseline ovarian reserve: evaluate antral follicle count and anti‑Müllerian hormone levels. - Monitor estradiol levels: frequent serum estradiol measurements to detect excessive response. - Screen for contraindications: avoid use in active ovarian cysts, uncontrolled thyroid disease, or malignancy. - Counsel on OHSS risk: educate patients about symptoms of ovarian hyperstimulation syndrome. - Review concomitant medications: consider potential interactions with estrogen‑containing products. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert can interact with other agents that influence ovarian response or hormone metabolism.

Major Interactions (Avoid): - Exogenous estrogen therapy: may exacerbate ovarian hyperstimulation. - Aromatase inhibitors: can blunt the intended estrogen rise and reduce efficacy.

Moderate Interactions (Monitor Closely): - Gonadotropin‑releasing hormone (GnRH) analogues: may require dose adjustments. - Anticoagulants: increased risk of thromboembolic complications if OHSS develops. - Thyroid hormone replacement: monitor thyroid function as hormonal changes may affect dosing.